Spotlight On... Texas team develops Zika mouse model

A team at the University of Texas Medical Branch has developed a mouse model to test Zika vaccines and treatments after three weeks, cutting down the usual process from a timeline of multiple months, the researchers said. Scott Weaver, UTMB virologist, told Reuters the team will run tests attempting to produce sexual transmission of Zika in the mice. The mouse model is anticipated to be integral in the search for a Zika vaccine, Weaver explained. The study was published in American Journal of Tropical Medicine and Hygiene. Report

> Researchers published findings in the journal Pediatrics showing that breastfeeding and new vaccines have lowered the rate of ear infections in infants. Report

> The Sabin Vaccine Institute named Amy Finan, currently an SVP at biotech industry group BIO, its next CEO, effective April 18. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Dengvaxia, Sanofi Pasteur's new dengue vaccine, was named the "Vaccine Breakthrough of 2016" at an awards event in Singapore. Release

And Finally... The Tribeca Film Festival's decision to pull antivaccination movie "Vaxxed: From Cover-Up to Catastrophe" triggered both support and outrage. Report (sub. req.)

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.